# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $6 pr...
Participants who completed the study rated higher treatment satisfaction with XP-8121 compared to oral and a majority (72%) ind...
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and lowers the pric...
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estima...
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement wit...
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives ...